авторефераты диссертаций БЕСПЛАТНАЯ БИБЛИОТЕКА РОССИИ

КОНФЕРЕНЦИИ, КНИГИ, ПОСОБИЯ, НАУЧНЫЕ ИЗДАНИЯ

<< ГЛАВНАЯ
АГРОИНЖЕНЕРИЯ
АСТРОНОМИЯ
БЕЗОПАСНОСТЬ
БИОЛОГИЯ
ЗЕМЛЯ
ИНФОРМАТИКА
ИСКУССТВОВЕДЕНИЕ
ИСТОРИЯ
КУЛЬТУРОЛОГИЯ
МАШИНОСТРОЕНИЕ
МЕДИЦИНА
МЕТАЛЛУРГИЯ
МЕХАНИКА
ПЕДАГОГИКА
ПОЛИТИКА
ПРИБОРОСТРОЕНИЕ
ПРОДОВОЛЬСТВИЕ
ПСИХОЛОГИЯ
РАДИОТЕХНИКА
СЕЛЬСКОЕ ХОЗЯЙСТВО
СОЦИОЛОГИЯ
СТРОИТЕЛЬСТВО
ТЕХНИЧЕСКИЕ НАУКИ
ТРАНСПОРТ
ФАРМАЦЕВТИКА
ФИЗИКА
ФИЗИОЛОГИЯ
ФИЛОЛОГИЯ
ФИЛОСОФИЯ
ХИМИЯ
ЭКОНОМИКА
ЭЛЕКТРОТЕХНИКА
ЭНЕРГЕТИКА
ЮРИСПРУДЕНЦИЯ
ЯЗЫКОЗНАНИЕ
РАЗНОЕ
КОНТАКТЫ


Pages:     | 1 | 2 ||

«Федеральное государственное бюджетное учреждение «Гематологический научный центр» Министерства здравоохранения Российской Федерации ...»

-- [ Страница 3 ] --

88. Kiladjian, J.J. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes / J.J. Kiladjian, E. Bourgeous, I. Lobe, T. Braun, G. Visentin, J.H. Bourhis, P. Fenaux, S. Chouaib, A. Caignard // Leukemia.

– 2006. – N 20. – p. 463-470.

89. Kim, M. Quantity of clonal cells detected by conventional cytogenetic analysis correlates with bone marrow blasts and survival in myelodysplastic syndrome / M. Kim, S. Chung, S.-S. Yooh, B.K. Kim, H.K. Kim, D.S. Lee // Leuk Res. – 2012. – N 36. – p. 163-168.

90. Klaus, M. Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes / M. Klaus, E. Stavroulaki, M.-C. Kastrinaki, P. Fragioudaki, K.

Giannikou, M. Psyllaki, C. Pontikoglou, D. Tsoukatou, C. Mamalaki, H.A. Papadaki // Stem Cells Develop. – 2010. - N 19. – p. 1043-1054.

91. Knospe, W.H. Smouldering acute leukaemia / W.H. Knospe, S.A. Gregory // Arch Intern Med. – 1971. – N 127. – p. 910-918.

92. Kronke, J. Biology of myelodysplastic syndrome / J. Kronke, B.L. Ebert // Hematology Education: the education program for annual congress of the EHA. – 2012. – N 6. – p. 237-244.

93. Lancrin, C. The haemangioblast generates hematopoietic cells through a haemogenic endothelium stage / C. Lancrin, P. Sroczynska, C. Staphenson, T. Allen, V. Kouskoff, G. Lacaud // Nature. – 2009. – N 457. – p. 892-895.

94. Langer-Safer, P.R. Immunological method for mapping genes on Drosophila polytene chromosomes / P.R. Langer-Safer, M. Levine, D.C. Ward // Proc Natl Acad Sci USA. – 1982. – N 79. – p. 4381-4385.

95. Lanza, F. Structural and functional features of the CD34 antigen: an update / F. Lanza, L. Healy, D.R. Sutherland // J Biol Regul Homeost Ag. – 2001. – N 15. – p.

1-13.

96. Le Beau, M.M. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases / M.M. le Beau, R.

Espinosa, E.M. Davis, J.D. Eisenbart, R.A. Larson, E.D. Green // Blood. – 1996. – N 88. – p. 1930-1935.

97. Linder, D. Glucose-6-phosphate dehydrogenase mosaicism: utilization as a cell marker in the study of leiomyomas / D. Linder, S.M. Gartler // Science. – 1965. – N 150. – p. 67-69.

98. List, A. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion / A. List, G. Dewald, J. Bennett, A. Giagounidis, A. Raza, E. Feldman, B.

Powell, P. Greenberg, D. Thomas et al. // New Engl J Med. – 2006. – N 355. – p.

1456-1465.

99. Lpez-Holgado, N. Analysis of hematopoietic progenitor cells in patients with myelodysplastic syndromes according to their cytogenetic abnormalities / N.

Lpez-Holgado, J.L. Arroyo, C. Pata, E. Villarn, F. Snchez Guijo, A. Martn, J.M.

Hernndez Rivas, A. Orfao, J.F. San Miguel, M.C. Del Caizo Fernndez-Roldn // Leuk Res. – 2004. – N 28. – p. 1181-1187.

100. Lopez-Villar, O. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome / O. Lopez-Villar, J.L. Garcia, F.M. Sanchez-Guijo, C. Robledo, E.M. Villaron, P. Hernandez-Campo, N. Lopez-Holqado, M. Diez-Campelo, M.V.

Barbado et al. // Leukemia. – 2008. – N 23. – p. 664-672.

101. Malcovati, L. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) / L. Malcovati, M.G. Della Porta, C. Strupp, I.

Ambaglio, A. Kuendgen, K. Nachtkamp, E. Travaglino, R. Invernizzi, C. Pascutto et al. // Haematologica. – 2011. – N 96. – 1433-40.

102. Mallo, M. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q- / M.

Mallo, L. Arenillas, B. Espinet, M. Salido, J.M. Hernndez, E. Lumbreras, M. del Rey, E. Arranz, S. Ramiro et al. // Haematologica. – 2008. – N 93. – p. 1001-1008.

103. Marsh, J.C. Recurrent graft failure following syngeneic bone marrow transplantation for aplastic anaemia / J.C. Marsh, N. Harhalakis, C. Dowding, E.C.

Gordon-Smith, J.M. Hows // Bone Marrow Transplant. – 1989. – N 4. – p. 581-585.

104. Marcondes, A.M. Myeloid malignancies and marrow microenvironment:

some recent studies in patients with MDS / A.M. Marcondes, A. Ramakrishman, H.J.

Deeg // Curr Cancer The Rev. – 2009. – N 5. – p. 310-314.

105. Marisavljevic, D. Biological implications of circulating CD34+ cells in myelodysplastic syndromes / D. Marisavljevic, N. Kraguljac-Kurtovic // J Buon. – 2010. – N 15. – p. 753-757.

106. Michels, S.D. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases / S.D.

Michels, R.W. McKenna, D.C. Arthur, R.D. Brunning // Blood. – 1985. – N 65. – p.

1364-1372.

107. Millard, R.E. Further observations on patients with a chromosomal abnormality associated with polycythaemia vera / R.E. Millard, S.D. Lawler, H.E.

Kay, C.B. Cameron // Br J Haematol. – 1968. – N 14. – p. 363-374.

108. Mitsiades, C.S. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions / C.S. Mitsiades, N.S.

Mitsiades, N.C. Munshi, P.G. Richardson, K.C. Anderson // Eur J Cancer. – 2006. – N 42. – p. 1564-1573.

109. Miura, I. Involvement of natural killer cells in patients with myelodysplastic syndrome carrying monosomy 7 revealed by the application of fluorescence in situ hybridization to cells collected by means of fluorescence-activated cell sorting / I. Miura, Y. Kobayashi, N. Takahashi, K. Saitoh, A.B. Miura // Br J Haematol. – 2000. – N 110. – p. 876-879.

110. Monreal, M.B. Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia / M.B. Monreal, M.L. Pardo, M.A. Pavlovsky, I.

Fernandez, C.S. Corrado, I. Giere, S. Sapia, S. Pavlovsky // Cytometry B Clin Cytom.

– 2006. – N 70. – p. 63-70.

111. Mueller, M.M. Friends and foes – bipolar effects of the tumor stroma in cancer / M.M. Mueller, N.E. Fusenig // Nature Rev Cancer. – 2004. – N 4. – p. 834 849.

112. Mufti, G.J. Coexistent myelodysplasia and plasma cell neoplasia / G.J.

Mufti, T.J. Hamblin, G.P. Clein, C. Race // Br J Haematol. – 1983. – N 54. – p. 91-96.

113. Muguruma, Y. Reconstitution of the functional human hematopoietic microenvironment derived from human mesenchymal stem cells in the murine bone marrow compartment / Y. Muguruma, T. Yahata, H. Miyatake, T. Sato, T. Uno, J.

Itoh, S. Kato, M. Ito, T. Hotta, K. Ando // Blood. – 2006. – N 107. – p. 1878-1887.

114. Musilova, J. Chromosome study of 85 patients with myelodysplastic syndrome / J. Musilova, K. Michalova / Cancer Genet Cytogenet. – 1988. – N 33. – p.

39-50.

115. Naveiras, O. Bone marrow adipocytes as negative regulators of the hematopoietic microenvironment / O. Naveiras, V. Nardi, P.L. Wenzel, P.V.

Hauschka, F. Fahey, G.Q. Daley // Nature. – 2009. – N 460. – p. 259-263.

116. Nilsson, L. Involvement and functional impairment of the CD34 +CD38 Thy+ hematopoietic stem cells pool in myelodysplastic syndromes with trisomy 8 / L.

Nilsson, I. Astrand-Grundstrom, K. Anderson, I. Arvidsson, P. Hokland, D. Bryder, L.

Kjeldsen, B. Johansson, E. Hellstrm-Lindberg et al. // Blood. – 2002. – N 100. – p.

259-267.

117. Nilsson, L. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level / L. Nilsson, I. Astrand-Grundstrom, I. Arvidsson, B.

Jacobsson, E. Hellstrom-Lindberg, R. Hast, SE. Jacobsen // Blood. – 2000. – N 96. – p. 2012-2021.

118. Nimer, S.D. MDS: A stem cell disorder – but what exactly is wrong with the primitive hematopoietic cells in this disease? / S.D. Nimer // Hematology ASH Education Program. – 2008. – p. 43-51.

119. Nowell, P.C. A minute chromosome in human chronic granulocytic leukemia / P.C. Nowell, D.A. Hungerford // Science. – 1960. – N 132. – p. 1497-1501.

120. Omatsu, Y. The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche / Y. Omatsu, T. Sugiyama, H. Kohara, G.

Kondoh, N. Fujii, K. Kohno, T. Nagasawa // Immunity. – 2010. – N 33. – p. 387-399.

121. Paget S. The distribution of secondary growths in cancer of the breast / S.

Paget // The Lancet. – 1889. – N 1. – p. 571-573.

122. Pang, W.W. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes / W.W. Pang, J.V. Pluvinagea, E.A. Price, K. Sridhar, D.A. Arber, P.L. Greenberg, S.L. Schrier, C.Y. Park, I.L. Weissman // Proc Natl Acad Sci USA. – 2013. – N 110. – p. 3011-3016.

123. Pasquali, F. Pathogenetic significance of pure monosomy 7 in myeloproliferatie disorders. Analysis of 14 cases / F. Pasquali, P. Bernasconi, R.

Casalone, M. Fraccaro, C. Bernasconi, M. Lazzarino, E. Morra, E.P. Alessandrino, M.A. Marchi, R. Sanger // Hum Genet. – 1982. – N 62. – p. 40-51.

124. Pierre, R.V. Cytogenetic studies in preleukemia: Studies before and after transition to acute leukemia in 17 subjects / R.V. Pierre // Blood Cells. – 1975. – N 1.

– p. 163-170.

125. Pilo, F. The evolving clinical scenario of myelodysplastic syndrome: The need for a complete and up to date upfront diagnostic assessment / F. Pilo, A.A. di Tucci, P. Dessalvi, A. Caddori, E. Angelucci // Eur J of Int Med. – 2010. – N 2. – p.

490–495.

126. Pittenger, M.F. Multilineage potential of adult human mesenchymal stem cells / M.F. Pittenger, A.M. Mackay, S.C. Beck, R.K. Jaiswal, R. Douglas, J.D. Mosca, M.A. Moorman, D.W. Simonetti, S. Craig, D.R. Marshak // Science. – 1999. – N 284.

– p. 143-147.

127. Prchal, J.T. A common progenitor for myeloid and lymphoid cells / J.T.

Prchal, D.W. Throckmorton, A.J. Carrol, E.W. Fuson, R.A. Gams, J.F. Prchal // Nature. – 1978. – N 274. – p. 590-591.

128. Raaijmakers, M. Bone progenitor dysfunction induces myelodysplasia and secondary leukemia / M. Raaijmakers, S. Mukherjee, S. Guo, S. Zhanq, T. Kobayashi, J.A. Schoonmaker, B.L. Ebert, F. Al-Shahrour, R.P. Hasserjian et al. // Nature. – 2010.

– N 464. – p. 852-857.

129. Ramakrishman, A. The stromal component of the marrow microenvironment is not derived from the malignant clone in MDS / A.

Ramakrishman, N. Awaya, E. Bryant, B. Torok-Storb // Blood. – 2006. – N 108. – p.

772-773.

130. Ramakrishnan, A. A novel role for the marrow microenvironment in initiating and sustaining hematopoietic disease / A. Ramakrishnan, H.J. Deeg // Expert Opin Biol Ther. – 2009. – N 9. – p. 21-28.

131. Raskind, W.H. Evidence for a multistep pathogenesis of a myelodysplastic syndrome / W.H. Raskind, N. Tirumali, R. Jacobson, J. Singer, P.J. Fialkow // Blood.

– 1984. – N 63. – p. 1318-1323.

132. Rhoads, C.P. Refractory anemia: analysis of 100 cases / C.P. Rhoads, W.H.

Barker // JAMA. – 1938. – N 110. – p. 794-796.

133. Rigolin, G.M. Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype / G.M. Rigolin, R. Bigoni, R. Milani, F. Cavazzini, M.G. Roberti, A. Bardi, P. Agostini, M. Della Porta, A. Tieghi // Leukemia. – 2001. – N 15. – p. 1841-1847.

134. Rowley, J.D. Nonrandom chromosome abnormalities in acute leukemic and dysmyelopoietic syndromes in patients with previously treated malignant disease / J.D. Rowley, H.M. Golomb, J.W. Vardiman // Blood. – 1981. – N 58. – p. 759-67.

135. Saitoh, K. Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes / K.

Saitoh, I. Miura, N. Takahashi, A.B. Miura // Blood. – 1998. – N 92. – p. 2886-2892.

136. Schanz, J. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge / J. Schanz, H. Tu chler, F. Sol e, M. Mallo, E. Luo, J. Cervera, I. Granada, B. Hildebrandt, M.L. Slovak et al. // J Clin Oncol. – 2012. – N 30. – p. 820-829.

137. Schroeder, T.M. Functional impairment and decreased osteogeneic differentiation capacity of mesenchymal stromal cells (MSC) from patients with myelodysplastic syndromes (MDS) result in insufficient stromal support for CD Hematopoietic Stem and Progenitor Cells (HSPC) / T.M. Schroeder, S. Geyh, R.-P.

Cadeddu, J. Frobel, S. Arends, A.-N. Hunerliturkoglu, A. Kundgen, D. Hemsen, R.

Fenk et al. // Onkologie. – 2012. – N 35. –– p. 16-17.

138. Seabright, M. Rapid banding technique for human chromosomes / M.

Seabright // The Lancet. – 1971. – N 2. – p. 971-972.

139. Second International Workshop on Chromosomes in Leukemia:

Chromosomes in preleukemia. Cancer Genet Cytogenet. – 1979. – N 2. – p. 108-113.

140. Sloand, E.M. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy myelodysplastic syndrome / E.M. Sloand, L. Mainwaring, M. Fuhrer, S. Ramkissoon, A.M. Risitano, K. Keyvanafar, J. Lu, A. Basu, A.J. Barrett, N.S. Young // Blood. – 2005. – N 106. – p. 841-51.

141. Sloand, E.M. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up- regulation of antiapoptotic proteins / E.M. Sloand, L. Pfanes, G. Chen, S. Shah, E.E. Solomou, J. Barrett, N.S. Young // Blood. – 2007. – N 109. – p. 2399-2405.

142. Soenen-Cornu, V. Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short - and long-term hematopoiesis in vitro / V. Soenen-Cornu, C. Tourino, M.L.

Bonnet, M. Guillier, S. Flamant, R. Kotb, A. Bernheim, J.H. Bourhis, C. Preudhomme, P. Fenaux, A.G. Turhan // Oncogene. – 2005. – N 24. – p. 2441-2448.

143. Song, L.-X. Bone Marrow Mesenchymal Stem Cells in Myelodysplastic Syndromes: Cytogenetic Characterization / L.-X. Song, J. Guo, Q. He, L.-P. Yang, Sh.-Ch. Gu, X. Zhang, L.-Y. Wu, X. Li, Ch.-K. Chang // Acta Haematol. – 2012. – N 128. – p. 170–177.

144. Steensma, D.P. Historical perspectives on myelodysplastic syndromes / D.P. Steensma // Leuk Res. – 2012. – N 36. – p. 1441–1452.

145. Stier, S. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size / S. Stier, Y. Ko, R. Forkert, C. Lutz, T.

Neuhaus, E. Grunewald, T. Cheng, D. Dombkowski, L.M. Calvi, S.R. Rittling, D.T.

Scadden // J Exp Med. – 2005. – N 201. – p. 1781-1791.

146. Swerdlow, S.H. WHO Classification of tumors of haematopoietic and lymphoid tissues / S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H.

Stein, J. Thiele, J.W. Vardiman // 4th edn, Lyon: IARC Press. – 2008. – 439 p.

147. Suciu, S. Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome / S.

Suciu, R. Kuse, H.J. Weh, D.K. Hossfeld // Cancer Genet Cytogenet. – 1990. – N 4. – p. 15-26.

148. Sugiyama, T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches / T.

Sugiyama, H. Kohara, M. Noda, T. Nagasawa // Immunity. – 2006. – N 25. – p. 977 988.

149. Sullivan, S.A. Circulating CD34+ cells: an adverse prognostic factor in the myelodysplastic syndromes / S.A. Sullivan, K.A. Marsden, R.M. Lowenthal, D.M.

Jupe, M.E. Jones // Am J Hematol. – 1992. – N 39. – p. 96–101.

150. Taichman, R.S. Human osteoblasts support human hematopoietic progenitor cells in vitro bone marrow cultures / R.S. Taichman, M.J. Reilly, S.G.

Emerson // Blood. – 1996. – N 87. – p. 518-524.

151. Tehranchi, R. Persistent malignant stem cells in del(5q) myelodysplasia in remission / R. Tehranchi, P.S. Woll, K. Andreson, N. Buza-Vidas, T. Mizukami, A.J.

Mead, I. Astrand-Grundstrom, B. Strombeck, A. Horvat, H. Ferry et al. // N Engl J Med. – 2010. – N 363. – p. 1025-1037.

152. Tjio, J.H. The chromosome number of man / J.H. Tjio, A. Levan // Hereditas. – 1956. – N 42. – p. 1-6.

153. Tomonaga, M. Sequential karoyotypic evolutions and bone marrow aplasia preceding acute myelomonocytic transformation from myelodysplastic syndrome / M.

Tomonaga, Y. Tomonaga, M. Kusano, M. Ichimaru // Br J Haematol. – 1984. – N 58.

– p. 53-60.

154. Tricot, G. The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations / G. Tricot, M.A.

Boogaerts, C. de Wolf-Peeters, H. van den Berghe, R.L. Verwilghen // Br J Haematol.

– 1985. – N 59. – p. 659-670.

155. Trost, D. Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia / D. Trost, B.

Hildebrandt, M. Beier, N. Mller, U. Germing, B. Royer-Pokora // Cancer Genet Cytogenet. – 2006. – N 165. – p. 51–63.


156. Van den Berghe, H. The 5q– Anomaly / H. van den Berghe, K.

Vermaelen, C. Mecucci, D. Barbieri, G. Tricot // Cancer Genet Cytogenet. – 1985. – N 17. – p. 189-255.

157. Van Epps, D.E. Harvesting, characterization, and culture of CD34+ cells from human bone marrow, peripheral blood, and cord blood / D.E. van Epps, J.

Bender, W. Lee, M. Schilling, A. Smith, S. Smith, K. Unverzagt, P. Law, J. Burgess // Blood cells. – 1994. – N 20. – p. 411-423.

158. Varga, G. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes / G. Varga, J. Kiss, J. Varkonyj, V. Vas, P. Paloczi, F. Uher // Pathol Oncol Res. – 2007. – N 13. – p. 311-319.

159. Vehmeyer, K. Increased peripheral stem cell pool in MDS: an indication of disease progression? / K. Vehmeyer, D. Haase, F. Alves // Leuk Res. – 2001. – N 25. – p. 955–959.

160. Walkley, C.R. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency / C.R. Walkley, G.H. Olsen, S.

Dworkin, S.A. Fabb, J. Swann, G.A. McArthur, S.V. Westmoreland, P. Chambon, D.T. Scadden, L.E. Purton // Cell. – 2007. – N 129 – p. 1097–1110.

161. Waller, E.K. The common stem cell‘ hypothesis reevaluated: human fetal bone marrow contains separate populations of hematopoietic and stromal progenitors / E.K. Waller, J. Olweus, F. Lund-Johansen, S. Huang, M. Nguyen, G.R. Guo, L.

Terstappen // Blood. – 1995. – N 85. – p. 2422–2435.

162. Warlick, E.D. Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches / E.D. Warlick, B.D. Smith // Curr Canc Drug Targ. – 2007. – N 7. – p. 541-558.

163. Watt, F.M. Out of eden: Stem cell and their niches / F.M. Watt, B.L. Hogan // Science. – 2000. – N 287. – p. 1427-1430.

164. Werner, M. Chromosome analysis in patients with myelodysplastic syndrome: correlation with bone marrow histopathology and prognosis significance / M. Werner, H. Maschek, V. Kaloutsi, H. Chritz, A. Georgii // Virchows Arch A Pathol Anat Histopathol. – 1992. – N 421. – p. 47-52.

165. Westers, T.M. Standardization of flow cytometry in myelodysplastic syndromes: a report from an International Consortium and the European Leukemia Net Working Group / T.M. Westers, R. Ireland, W. Kern, C. Alhan, J.S. Balleisen, P.

Bettelheim, K. Burbury, M. Cullen, J.A. Cutler, M.G. Della Porta et al.// Leukemia. – 2012. – N 26. – p. 1730- 1741.

166. White, N.J. Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells / N.J. White, E. Nacheva, F.A.

Asimakopoulos, D. Bloxham, B. Paul, A.R. Green // Blood. – 1994. – N 83. – p. 2809 2816.

167. Will, B. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterarions / B.

Will, L. Zhou, T.O. Vogler, S. Ben-Neriah, C. Schinke, R. Tamari, Y. Yu, T.D.

Bhagat, S. Bhattacharyya et al. // Blood. – 2012. – N 120. – p. 2076-2086.

168. Yunis, J.J. Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes / J.J. Yunis, R.E. Rydell, M.M. Oken, M.A. Arnesen, M.G. Mayer, M. Lobell // Blood. – 1986. – N 67. – p. 1721-1730.

169. Zhang, Z.X. Cytogenetic analysis of human bone marrow derived mesenchymal stem cells passaged in vitro / Z.X. Zhang, LX. Guan, K. Zhang, S.

Wang, P.C. Cao, Y.H. Wang, Z. Wang, L.J. Dai // Cell Biol Int. – 2007. – N 31. – p.


645-648.

Приложение Таблица Результаты цитогенетических исследований общей популяции клеток костного мозга и МСК Клетки костного мозга МСК № Пол, пациен- возраст Диагноз № та Кариотип Маркер пассажа Кариотип Маркер МСК FISH (%) FISH (%) М, 74 МДС: РАИБ- 001 46,ХY[20] 2 46,ХY[20] 46,ХY,-7,inv(9) (p13q21), М, 33 МДС: РАИБ- 002 i(17)(9q10), +22[19]/ -7(80%) 5 46,ХY, -7(0%) 46,ХY, inv(9)(p13q21)[1] inv(9)(p13q21)[20] Ж, 49 МДС: 5q 003 46,ХХ[20] del(5q)(75%) 4 46,ХХ[20] del(5q)(0%) нет, IgH 46,ХY,i(14)(q10)[7]/ (14q34)(0%) М, 63 МДС: РАИБ- 004 46,ХY[13] 4 46,ХY[20] del(5q)(90%) н/м Ж, 57 МДС: РА -7(90%) 005 45,ХХ,del(5)(q31;

q35),-7[20] Ж, 61 МДС: РЦМД 006 45,ХХ,-7[17]/46,ХХ[3] -7(60%) 5 46,ХХ[20] -7(0%) нет, -5/del(5q), н/м -7/del(7q), +8 Ж, 53 МДС: РА 007 46,ХХ[20] (0%) нет, -5/del(5q), М, 57 МДС: РЦМД -7/del(7q), +8 008 46,ХY[20] (0%) 46,ХY,t(2;

22) нет, -5/del(5q), (p10;

q11), -7/del(7q), +8 3 inv(9)(p13q21)[1]/ М, 63 МДС: РАИБ- 009 46,ХY,inv(9)(p13q21)[20] (0%) 46,ХY,inv(9)(p13q21) [19] нет, -5/del(5q), М, 60 МДС: РАИБ- 010 46,ХY[20] -7/del(7q), +8 2 46,ХY[7] (0%) нет,-5/del(5q), Ж, 64 МДС: РАИБ- 011 46,ХХ[20] -7/del(7q), +8 3 46,ХХ[20] (0%) del(5q)(84%) del(5q)(0%) Ж, 67 МДС: РАИБ-2 н/м 012 del(7q)(84%) 3 46,ХХ[20] del(7q)(0%) 46,ХХ,del5(q15q33)[11]/ del(5q)(85%) Ж, 55 МДС: 5q 013 46,ХХ[9] 2 46,ХХ[20] del(5q)(0%) н/м Ж, 60 МДС: РЦМД н/м +8(67%) 51,ХY,+Y,+3,+6,+8, М, 42 МДС: РАИБ-1 +Y(77%) 015 del(9) (q13),+del(9) 3 46,ХY[20] +Y(0%) +8(76%) (q13)[19]/46,ХY[1] 45-46,ХY,-?5,-13,der(19), add(q13?or p13?),-20,+mar М, 58 МДС: РЦМД х2,+mar?del(13q21)[15]/ 016 del(5q)(74%) 2 46,ХY,add(2q)[7]/ del(5q)(0%) 45-46,ХY idem,+dmin[2]/ -20(70%) 46,ХY[13] 46,ХY[3] нет, -5/del(5q), М, 60 МДС: РЦМД 017 46,ХY[20] -7/del(7q), +8 2 46,ХY[20] (0%) нет, -5/del(5q), Ж, 29 МДС: РЦМД 018 46,ХХ[20] -7/del(7q), +8 2 46,ХХ[20] (0%) нет, -5/del(5q), М, 73 МДС: РАКС 019 46,ХY[20] -7/del(7q), +8 2 46,ХY[20] (0%) нет, -5/del(5q), М, 77 МДС: РАИБ-1 н/м н/м 020 -7/del(7q), +8 (0%) М, 56 МДС: РЦМД 021 46,ХY[20] 2 46,XY[20] Ж, 61 МДС: РЦМД 022 46,ХХ,inv(3)(q21;

q26)[11] inv(3)(45%) 2 46,ХХ[20] inv(3)(0%) нет, -5/del(5q), Ж, 51 МДС: РЦМД 023 46,ХХ[20] -7/del(7q), +8 2 46,ХХ[20] (0%) нет, -5/del(5q), Ж, 44 МДС: РЦМД 46,ХХ [20] н/м 024 -7/del(7q), +8 (0%) нет, -5/del(5q), Ж, 37 МДС: РАКС н/м 025 46,ХХ[20] -7/del(7q), +8 (0%) нет, -5/del(5q), Ж, 71 МДС: РЦМД н/м 026 46,ХХ[20] -7/del(7q), +8 (0%) нет, -5/del(5q), М, 43 МДС: РАКС 027 46,ХY[20] -7/del(7q), +8 2 46,ХY[20] (0%) М, 48 МДС: РЦМД 028 46,ХY,del(5)(q15q33)[10]/ del(5q)(80%) 46,ХY[10] +21(52%) 46,ХY,del(5)(q15q33)[7]/ М, 62 МДС: 5q- del(5q)(27%) 029 46,ХY[11] 46,ХX,del(5)(q15q33)[3]/ Ж, 52 МДС: РАИБ-1 н/р del(5q)(76%) 030 46,ХX[6] Ж, 73 МДС: РАИБ-2 н/р -7(67%) 031 45,ХХ,-7[18]/46,ХХ[2] -7(23%) 45,ХХ,-7[5]/ -7(0%) +Х(20%) Ж, 48 МДС: РАИБ-1 +Х(4%) 032 47,ХХХ[9]/46,ХХ[6] 2 46,ХX[7] Ж, 38 МДС: РАИБ-2 +8(19%) 033 46,ХX[20] 2 46,ХX[20] нет, -5/del(5q), М, 64 МДС: РЦМД 034 46,ХY[20] -7/del(7q), +8 2 46,ХY[20] (0%) нет, -5/del(5q), Ж, 53 МДС: РЦМД 035 46,ХX[20] -7/del(7q), +8 2 46,ХX[7] (0%) М, 63 в-МДС: РАИБ-2 н/р -7(45%) 036 46,ХY[20] М, 19 ОМЛ 037 45,ХY,-7[18]/46ХY[2] 2 46,ХY[20] нет, -5/del(5q), М, 77 ОМЛ н/м 038 46,ХY[20] -7/del(7q), +8 (0%) Ж, 58 ОМЛ 039 46,ХХ[20] 3 46,ХХ[20] М, 76 ОМЛ del(5q)(67%) 040 46,ХY[20] 3 46,ХY[20] del(5q)(0%) 47,ХХ,del(9)(q22),del(12) (p13),-?21,+mar, Ж, 64 в-ОМЛ н/м 041 del(21)(?q11) +mar[5]/ +21(25%) - +21(0%) 46,ХХ[15] 46-47,ХХ,der(3),?-5 or ?del(5)(q13q33),?der(7) or ?del(7)(22),del(p10) (q22), Ж, 66 ОМЛ 042 der(12)add (q24), -?17 or * 2 46,ХХ[20] ?der(17) add(p11) or ?t(7;

17) (p10q10),+mar1-2[20] нет, -5/del(5q), Ж, 59 ОМЛ н/м н/р 043 -7/del(7q), +8 (0%) Примечание: М – мужчина, Ж – женщина, МДС - миелодиспластический синдром, МСК – мезенхимальные стромальные клетки, РА – рефрактерная анемия, РАИБ – рефрактерная анемия с избытком бластов, РЦМД – рефрактерная цитопения с мультилинейной дисплазией, в МДС – вторичный МДС, ОМЛ - острый миелоидный лейкоз, в-ОМЛ – вторичный ОМЛ, н/м – нет митозов, н/р – нет роста, - не исследовали Таблица Характеристика лабораторных показателей пациентов с МДС. Распределение по группам риска в соответствии с критериями шкал IPSS, WPSS и IPSS-R Гем Л АЧН Тр БК ТЗ IPSS (баллы) WPSS (баллы) IPPS-R (баллы) № (х10 /л) (х109/л)(х109/л) (г/л) КМ(%) п-та Да Промежуточный-2(1,5) Высокий (4) Высокий (5,5) 001 77 7,7 4,8 134 19, Да Высокий(3) Очень высокий (6) Очень высокий (9) 002 72 2,1 0,3 6 12, Нет Низкий (0) Очень низкий (0) Низкий (3) 003 84 4,2 2,9 496 4, Нет Промежуточный-2 (2) Высокий (4) Высокий (5,5) 004 103 6,6 4,0 90 14, Нет Промежуточный-2(1,5) Промежуточный (2) Промежуточный (5) 005 84 3,4 0,9 309 4, Да Промежуточный-2(1,5) Высокий (4) Высокий (5,5) 006 93 2,7 0,4 44 0, Да Промежуточный-1(0,5) Низкий (1) Промежуточный(4,5) 007 71 2,5 1,0 10 2, Нет Низкий (0) Низкий (1) Низкий (2) 008 119 3,5 1,8 46 0, Да Промежуточный-2(1,5) Высокий (4) Промежуточный (4) 009 120 3,1 1,5 130 19, Да Промежуточный-1(1) Высокий (3) Высокий (5) 010 94 2,7 0,1 55 9, Да Промежуточный-2(2) Высокий (4) Высокий (6) 011 67 3,9 1,6 61 17, Да Высокий (3) Очень высокий (6) Очень высокий (8,5) 012 70 2,0 0,7 62 11, Да Низкий (0) Низкий (1) Промежуточный (3,5) 013 75 2,6 1,6 266 3, Да Промежуточный-1(0,5) Высокий (3) Промежуточный (4,5) 014 61 2,5 2,0 150 4, Да Промежуточный-2(2) Очень высокий (5) Очень высокий (8,5) 015 85 2,2 0,2 25 5, Да Промежуточный-2(1,5) Высокий (4) Высокий (6) 59 5,8 3,5 55 1, Да Низкий (0) Промежуточный (2) Низкий (2,5) 017 68 5,5 4,2 405 0, Нет Низкий (0) Низкий (1) Низкий (2,5) 018 138 5,1 3,4 50 2, Нет Низкий (0) Очень низкий (0) Низкий (2) 019 92 7,6 5,0 475 2, Нет 020 92 5,8 3,1 68 8,5 - - Нет Низкий (0) Низкий (1) Низкий (2,5) 021 111 2,7 1,2 84 4, Нет Промежуточный-1(0,5) Промежуточный (2) Промежуточный (4) 022 88 5,3 4,4 130 1, Нет Низкий (0) Низкий (1) Низкий (3) 023 89 6,0 3,8 330 2, Да Промежуточный-1(0,5) Промежуточный (2) Промежуточный (4,5) 024 69 4,5 2,7 16 4, Нет Промежуточный-1(0,5) Очень низкий (0) Низкий (2) 025 98 2,3 0,9 168 0, Да Низкий (0) Промежуточный (2) Низкий (2,5) 026 71 2,9 2,0 207 0, Нет Низкий (0) Очень низкий (0) Низкий (2) 027 85 3,7 2,0 170 0, Нет Низкий (0) Низкий (1) Низкий (3) 028 94 6,0 4,5 710 3, Да Промежуточный-1(0,5) Низкий (1) Низкий (3) 029 89 3,3 0,8 604 4, Да Промежуточный-1(1) Высокий (3) Высокий (5,5) 030 62 3,8 2,4 34 6, Да Высокий (3) Очень высокий (6) Очень высокий (7,5) 031 88 3,0 1,7 79 12, Нет Промежуточный-2(1,5) Высокий (4) Высокий (6) 032 102 2,8 2,0 47 7, Да Высокий (2,5) Очень высокий (5) Очень высокий (7,5) 033 90 2,2 0,4 37 18, Да Промежуточный-1(0,5) Промежуточный (2) Промежуточный (4,5) 63 2,2 1,7 44 3, Да Промежуточный-1(0.5) Промежуточный (2) Низкий (2,5) 035 80 2,7 0,8 56 1, Нет 036 92 3,3 1,5 40 11,4 - - Примечание: Гем – гемоглобин;

Л – лейкоциты;

АЧН – абсолютное число нейтрофилов;

Тр – тромбоциты;

БК – бластные клетки;

КМ – костный мозг;

ТЗ – трансфузионная зависимость.



Pages:     | 1 | 2 ||
 





 
© 2013 www.libed.ru - «Бесплатная библиотека научно-практических конференций»

Материалы этого сайта размещены для ознакомления, все права принадлежат их авторам.
Если Вы не согласны с тем, что Ваш материал размещён на этом сайте, пожалуйста, напишите нам, мы в течении 1-2 рабочих дней удалим его.